The immune system can be retrained to accept what it once rejected.
In Stockholm, researchers at Karolinska Institutet have offered a quiet but profound reordering of what parents once accepted as permanent fate: that a child born with a peanut allergy must carry that burden for life. Through a carefully supervised process of gradual exposure beginning in toddlerhood, the immune system — still young and malleable — can be guided toward acceptance rather than alarm. The findings, published in The Lancet Regional Health – Europe, suggest that the earliest years of life may hold a window of opportunity that medicine is only beginning to understand how to open.
- Peanut allergy has long shadowed childhood with fear of accidental exposure and life-threatening reactions — but a Swedish trial is challenging the assumption that avoidance is the only path.
- 82% of treated toddlers could safely eat multiple peanuts after three years, compared to just 12% in the control group, a gap that signals a genuine shift in what treatment can achieve.
- The regimen was not without risk — a small number of children required adrenaline injections during dose-escalation phases, underscoring that this is a medical intervention, not a home experiment.
- Sweden's National Board of Health and Welfare has already responded, updating national allergy guidelines in April 2026 to recommend immunotherapy for children with severe peanut allergies.
- Researchers are now tracking whether the tolerance children built will last, and how the immune system is being changed at a biological level — the deeper story is still unfolding.
At Karolinska Institutet in Stockholm, a clinical trial has produced results that researchers themselves described as surprisingly positive: toddlers with peanut allergies, treated with daily oral immunotherapy over three years, largely learned to tolerate the very food their immune systems had rejected. The study, published in The Lancet Regional Health – Europe, enrolled 75 children aged one to three — fifty receiving treatment, twenty-five avoiding peanuts entirely as a control group.
The treatment began in a hospital with a tiny initial dose of peanut puffs, a dissolvable form chosen for its practicality with young children. Doses were increased every four to six weeks until children reached a daily maintenance level of roughly one and a half peanuts. After three years, 82% of treated children could safely consume at least three and a half peanuts — even after a four-week break from treatment. In the control group, only 12% reached that threshold.
The results carry weight beyond the numbers. Peanut allergy is frequently a lifelong condition, and families live under the constant pressure of accidental exposure. Sweden's National Board of Health and Welfare took notice, releasing updated guidelines in April 2026 that explicitly recommend immunotherapy for children with severe peanut allergies — a shift from management through avoidance toward treatment that can alter the disease's course.
Risks were present and honestly reported. Most side effects were mild — mouth itching, skin rashes — but a few children experienced severe reactions during dose escalation and required adrenaline injections. Lead researchers Caroline Nilsson and Anna Asarnoj were clear: this protocol depends on medical oversight and cannot be replicated safely at home.
What remains open is whether the tolerance children built will persist over time, and what the treatment is doing to the immune system at a deeper level. Those questions will guide the next phase of research. For now, the study offers families something that was not available before — evidence that a peanut allergy diagnosed in toddlerhood need not define a child's entire life.
In Stockholm, researchers at Karolinska Institutet have demonstrated that very young children with peanut allergies can learn to tolerate the food through a carefully controlled process of gradual exposure. The study, published in The Lancet Regional Health – Europe, involved 75 toddlers aged one to three years—fifty of whom received daily oral immunotherapy with peanut puffs, while twenty-five served as a control group that avoided peanuts entirely.
The treatment began in a hospital setting with a tiny initial dose, then continued at home under medical supervision. Every four to six weeks, the amount was increased incrementally until the children reached a maintenance level of roughly one and a half peanuts per day. The choice of peanut puffs—a form that dissolves easily in the mouth—made the regimen practical for families to manage. After three years, eighty-two percent of the treated children could safely eat at least three and a half peanuts without an allergic reaction, even after taking a four-week break from treatment. In the control group, only twelve percent achieved that tolerance.
The results matter because peanut allergy is often a lifelong condition that casts a shadow over childhood. Parents live with the constant fear of accidental exposure and severe reaction. In April 2026, Sweden's National Board of Health and Welfare released new allergy care guidelines explicitly recommending that more children with severe peanut allergies be offered immunotherapy—treatments that can fundamentally alter the disease's course rather than simply managing it through avoidance.
The study enrolled children with allergies ranging from mild symptoms to severe reactions upon ingestion. Side effects during treatment were mostly minor—itching in the mouth, skin rashes—but the researchers did not minimize the risks. A few children experienced serious allergic reactions during the dose-escalation phases and required adrenaline injections. This is why the researchers emphasize repeatedly that the treatment must happen in a healthcare setting with close medical oversight. It is not something a parent should attempt at home.
Caroline Nilsson, an associate professor at Karolinska Institutet and senior consultant at Sachs' Children and Youth Hospital, noted the surprise at how well the approach worked. "The peanut puffs were easily ingested, which made the treatment simple for families to follow, and we were surprised by how positive the results were," she said. Anna Asarnoj, who led the study alongside Nilsson, stressed the importance of caution: "The cautious treatment approach appears to play an important role in safety, but this is not something that parents should attempt at home, as serious reactions can still occur."
What happens next is still being written. The researchers plan to analyze how the immune system changes during treatment and to follow the children over a longer period to determine whether the tolerance they've built actually persists. The study was funded by a private donation, regional health funds, and the Swedish Asthma and Allergy Association. Some authors disclosed fees from pharmaceutical companies, though these were unrelated to the current work.
For families with toddlers facing peanut allergies, this research opens a door that was previously closed. It suggests that the allergy need not be a permanent sentence—that with patience, precision, and professional care, a child's immune system can be retrained to accept what it once rejected.
Citações Notáveis
The peanut puffs were easily ingested, which made the treatment simple for families to follow, and we were surprised by how positive the results were.— Caroline Nilsson, associate professor at Karolinska Institutet
The cautious treatment approach appears to play an important role in safety, but this is not something that parents should attempt at home, as serious reactions can still occur.— Anna Asarnoj, associate professor at Karolinska Institutet, study co-leader
A Conversa do Hearth Outra perspectiva sobre a história
Why does this matter for toddlers specifically? Why not just wait until they're older?
The immune system is more plastic in early childhood. If you can establish tolerance before the allergy becomes deeply entrenched, you're working with biology that's still forming. By age three, you've potentially prevented years of anxiety and dietary restriction.
The control group—the kids who just avoided peanuts—only twelve percent developed tolerance on their own. What does that tell us?
That avoidance alone doesn't solve the problem. The immune system doesn't forget; it doesn't gradually become comfortable with something you never expose it to. Tolerance requires active retraining, not passive waiting.
A few kids needed adrenaline injections. How do you square that with calling it safe?
Safety here doesn't mean risk-free. It means managed risk. The reactions happened in a hospital where they could be treated immediately. The alternative—a child having a severe reaction at home or school because no one knew how to help them—is far more dangerous.
Why peanut puffs specifically?
They dissolve easily, so there's no choking risk and no struggle with a toddler who won't swallow a pill or powder. The form matters as much as the dose. If families can't actually do the treatment, the science doesn't matter.
What's the next question the researchers are asking?
Whether the tolerance sticks. Three years is meaningful, but does it last into adolescence? And they want to understand the immune mechanism—what's actually changing in the body that allows it to accept peanuts. That knowledge could unlock treatments for other allergies too.
If this works, does it change how we think about food allergies in general?
Potentially. It challenges the idea that allergies are fixed, unchangeable facts. It suggests that with the right protocol, the right timing, and the right support, you can rewrite the immune system's response. That's a fundamentally different approach than just managing around the allergy forever.